Daiichi Sankyo Company, Limited
4568
Pozycja w akcjach
#729
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Cena akcji
$18.01
Kapitalizacja rynkowa
$32.77B
Zmiana (1 dzień)
0.14%
Zmiana (1 rok)
-30.22%
Kraj
JP
Handel Daiichi Sankyo Company, Limited (4568)
Kategoria
Healthcare
Wskaźnik P/S dla Daiichi Sankyo Company, Limited (4568)
Wskaźnik P/S na dzień October 2026 TTM: 2.32
Według najnowszych raportów finansowych i ceny akcji Daiichi Sankyo Company, Limited, obecny wskaźnik P/S (TTM) wynosi 2.32. Na koniec 2025 wynosił 3.53.
Historia wskaźnika P/S dla Daiichi Sankyo Company, Limited od 2001 do 2026
Wskaźnik P/S na koniec każdego roku
| Rok | Wskaźnik P/S | Zmień |
|---|---|---|
| 2026 (TTM) | 2.32 | -34.23% |
| 2025 | 3.53 | -36.82% |
| 2024 | 5.59 | -22.73% |
| 2023 | 7.23 | 47.08% |
| 2022 | 4.92 | -24.35% |
| 2021 | 6.50 | 32.44% |
| 2020 | 4.91 | 27.54% |
| 2019 | 3.85 | 58.68% |
| 2018 | 2.42 | 37.56% |
| 2017 | 1.76 | 0.78% |
| 2016 | 1.75 | 19.75% |
| 2015 | 1.46 | 33.47% |
| 2014 | 1.09 | -10.61% |
| 2013 | 1.22 | 8.22% |
| 2012 | 1.13 | -3.23% |
| 2011 | 1.17 | -9.73% |
| 2010 | 1.29 | -6.61% |
| 2009 | 1.39 | -42.59% |
| 2008 | 2.41 | -14.72% |
| 2007 | 2.83 | 33.04% |
| 2006 | 2.13 | 15.39% |
| 2005 | 1.84 | 23.64% |
| 2004 | 1.49 | 19.99% |
| 2003 | 1.24 | -38.43% |
| 2002 | 2.02 | -16.38% |
| 2001 | 2.41 | 0.00% |
Wskaźnik P/S dla podobnych firm lub konkurentów
| Firma | Wskaźnik P/S | Różnica wskaźnika P/S | Kraj |
|---|---|---|---|
| 15.44 | 565.27% |
US
|
|
| 6.36 | 174.11% |
US
|
|
| 7.81 | 236.59% |
US
|
|
| 5.67 | 144.34% |
US
|
|
| 4.44 | 91.26% |
CH
|
